Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

33 trials with published results (46%)

Research Maturity

60 completed trials (85% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

2.8%

2 terminated out of 71 trials

Success Rate

96.8%

+10.3% vs benchmark

Late-Stage Pipeline

75%

53 trials in Phase 3/4

Results Transparency

55%

33 of 60 completed with results

Key Signals

33 with results97% success

Data Visualizations

Phase Distribution

66Total
Not Applicable (4)
P 1 (5)
P 2 (4)
P 3 (39)
P 4 (14)

Trial Status

Completed60
Unknown5
Not Yet Recruiting2
Recruiting2
Terminated2

Trial Success Rate

96.8%

Benchmark: 86.5%

Based on 60 completed trials

Clinical Trials (71)

Showing 20 of 20 trials
NCT04544774RecruitingPrimary

The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy

NCT07459452Phase 2Not Yet RecruitingPrimary

Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis

NCT01861522Phase 3CompletedPrimary

The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT01425632Phase 3CompletedPrimary

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT01900054Phase 3CompletedPrimary

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT07157462Not ApplicableRecruitingPrimary

Investigation of the Effects of a Multispecies Probiotic Formulation on Perennial Allergic Rhinitis

NCT07231861Phase 1Not Yet Recruiting

Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers

NCT05299086Phase 3CompletedPrimary

As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis

NCT05122143Not ApplicableCompletedPrimary

Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

NCT00732368Phase 3CompletedPrimary

A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)

NCT01852812Phase 3CompletedPrimary

Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)

NCT01918033Phase 3CompletedPrimary

A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)

NCT00359216Phase 4CompletedPrimary

The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)

NCT06180083Phase 1Completed

Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray

NCT04874714Phase 3Terminated

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

NCT04024033Not ApplicableUnknownPrimary

Effects of Pine Cone Extract on Serum IgE Levels in Perennial Rhinitis

NCT05400811Phase 3Unknown

Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

NCT00794599Phase 4Completed

Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)

NCT00794846Phase 4Completed

Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)

NCT00794495Phase 4Completed

Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)

Scroll to load more

Research Network

Activity Timeline